# Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

> **NCT00004064** · PHASE2 · UNKNOWN · sponsor: **AltaRex** · enrollment: 102 (estimated)

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **BIOLOGICAL:** oregovomab

## Key facts

- **NCT ID:** NCT00004064
- **Lead sponsor:** AltaRex
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1998-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2013-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004064, "Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00004064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*